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Eight bifidobacterial strains isolated from human breast milk have been tested for their abilities to convert linoleic acid (LA) and
𝛼-linolenic acid (LNA) to conjugated linoleic acid (CLA) and conjugated 𝛼-linolenic acid (CLNA), respectively. These bioactive
lipids display important properties that may contribute to the maintenance and improvement human health. Three selected
Bifidobacterium breve strains produced CLA from LA and CLNA from LNA in MRS (160–170 and 210–230 𝜇gmL−1, resp.) and,
also, in reconstituted skim milk (75–95 and 210–244𝜇gmL−1, resp.). These bifidobacterial strains were also able to simultaneously
produce both CLA (90–105𝜇gmL−1) and CLNA (290–320 𝜇gmL−1) in reconstituted skimmilk. Globally, our findings suggest that
these bifidobacterial strains are potential candidates for the design of new fermented dairy products naturally containing very high
concentrations of these bioactive lipids. To our knowledge, this is the first study describing CLNA production and coproduction of
CLA and CLNA by Bifidobacterium breve strains isolated from human milk in reconstituted skim milk.
1. Introduction
Conjugated linoleic acid (CLA) and conjugated 𝛼-linolenic
acid (CLNA) are bioactive lipids with potentially relevant
benefits to human health. They have been shown to have
in vitro and in vivo anticarcinogenic, antiatherogenic, anti-
inflammatory, and antidiabetic activities and ability to reduce
body fat [1, 2].
In relation to CLA, the bioactive isomer cis 9, trans 11
CLA is the most abundant in the diet, constituting more
than 90% of the total CLA content in milk fat [2, 3]. On the
other hand, theCLNA isomers resulting from themetabolism
of intestinal and rumen bacteria are cis 9, trans 11, cis 15
CLNA and trans 9, trans 11, cis 15CLNA [1].The predominant
isomer is cis 9, trans 11, cis 15 CLNA, which has been detected
at low concentrations in milk fat [4, 5]. Presence of CLA
and CLNA isomers in ruminant milk fat are the result of
microbial partial biohydrogenation of dietary linoleic (LA) or
𝛼-linolenic (LNA) acid to stearic acidmetabolism pathway in
the rumen by the action of the linoleic acid isomerase [6].
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CLA may also be formed through endogenous conversion
of trans-vaccenic acid by the enzyme Δ9-desaturase in the
mammary gland [7–9].
Nevertheless, as the current nutritional recommenda-
tions for whole fat dairy products are that their consumption
should be limited, the CLA and CLNA content of human diet
is too low for obtaining health beneficial effects. Therefore,
a promising strategy to increase human intake of these
bioactive lipids would be to include CLA and/or CLNA-
producer bacteria in fermented dairy products. In the last
years, several studies have reported that some lactic acid
bacteria and bifidobacterial strains are able to efficiently
convert LA to CLA in milk, milk-based media, and dairy
products [10–12]. Moreover, other study demonstrated that
a CLA-producing Bifidobacterium breve strain can be applied
for the development of functional dairy products when used
as a started culture [13]. In contrast, at present, we have not
found studies showing CLNA production by bacteria in milk
and dairy products. In this context, the aim of the present
workwas to evaluate the ability of some bifidobacterial strains
isolated from human breast milk to produce CLA and/or
CLNA when growing not only in MRS broth but also in
reconstituted skim milk. In this study, we demonstrated that
some Bifidobacterium breve strains are able to (co)produce
CLA and CLNA in both media.
2. Material and Methods
2.1. Analytical Reagents. All reagents used in the lab pro-
cedures were of HPLC grade: hexane and sulphuric acid
were obtained from Labscan (Dublin, Ireland), linoleic acid
(C18:2 cis 9 cis 12) from Sigma-Aldrich (St. Louis, MO,
USA), linolenic acid (C18:3 cis 9 cis 12 cis 15) from Nu-
Chek Prep, Inc. (Elysian, USA), and high CLA content oil
(Tonalin) from Cognis (Illertissen, Germany). LA and LNA
were prepared as a 30000 𝜇gmL−1 stock solution containing
2% (w/v) Tween 80 (Scharlau, Sentmenat, Barcelona, Spain)
and filter-sterilized through a 0.45𝜇m-pore size membrane
(Sarstedt, Nu¨mbrecht, Germany).
2.2. Bacterial Strains, Growth Media, and Conditions. Eight
bifidobacterial strains previously isolated from human milk
[14, 15] were used in the study (Table 1). The bacterial strains
were grown overnight at 37∘C in MRS broth supplemented
with 0.05% (w/v) L-cysteine-HCL (Sigma) and 0.1% (w/v)
Tween-80 (MRS-Cys broth) under anaerobic conditions in
an anaerobic station (Bactron II, Shellab, Cornelius, Oregon,
USA). Three percent (v/v) of these cultures were trans-
ferred to fresh MRS-Cys broth (10mL) containing free LA
(500𝜇gmL−1) and/or free LNA (500𝜇gmL−1) and incubated
at 37∘C for 24 hunder anaerobic conditions.The sampleswere
analyzed when the bifidobacterial strains reach the early sta-
tionary phase, obtaining concentrations of ∼1 × 109 cfumL−1.
Only the strains that showed CLA production in MRS-Cys
broth after an initial qualitative screening were subsequently
tested for CLA and/or CLNA production in 10% skim milk
(Scharlau, Sentmenat, Barcelona, Spain) supplemented with
Table 1: CLA production level by the bifidobacterial strains
screened in this study.
Strains Production of CLA
Bifidobacterium breve ZL12-22 −∗
Bifidobacterium breve ZL12-28 +++
Bifidobacterium breve 29M2 +++
Bifidobacterium breveM7-70 +++
Bifidobacterium infantis ZL50-25 −
Bifidobacterium longum ZL89-79 −
Bifidobacterium longum ZL114-24A −
Bifidobacterium longum ZL114-24B −
∗(−)Noproduction; (+) slight production; (++)moderate production; (+++)
high production.
0.05% (w/v) L-cysteine and 0.8% (w/v) casamino acids (milk-
based medium), as described above.
Since the production of CLA and CLNA by the three
selected Bifidobacterium strains in MRS-Cys was similar,
B. breve M7-70 was chosen as the model strain for the
subsequent assays. First, the sensitivity of B. breve M7-70 to
different concentrations of LA or LNA (0, 250, 500, 1000,
1500, and 2000𝜇g/mL)was evaluated inMRS-Cys broth since
LA and LNA have antimicrobial properties. Then, this strain
was submitted to a comparative analysis of CLA versusCLNA
production at different times (0, 1, 2, 3, 4, 6, 8, 24, and 48 h)
in MRS-Cys broth.
2.3. Qualitative Screening of CLA Producers by UV Spec-
troscopy Method. Lipid isolation from culture media was
carried out using a chloroform/methanol (2 : 1, v/v) solution
according to Folch method modified by [16]. The lipid
residues obtained were subjected to a N
2
flow and remained
dissolved in chloroform at −20∘C until spectrophotometric
analysis. For this analysis, lipid extracts (200𝜇L) from each
sample were placed on a quartz 96-well plate (Hellma GmbH
&Co. KG,Mu¨llhein, Germany) and total CLAwas quantified
at a wavelength of 233 in a spectrophotometer (Varioskan
Flash,Thermo Fisher Scientific,Waltham,MA,USA) accord-
ing to [10]. Measurements were obtained in triplicate.
2.4. Quantitative Analysis of CLA and CLNA Production.
The concentrations of CLA and CLNA in the culture media
were determined using a direct transesterification method
[17]. Heptadecanoic acid (C17:0; Sigma) was added to the
samples as an internal standard. The fatty acid methyl esters
(FAMEs) were dissolved in n-hexane and determined by gas
liquid chromatography (GLC) in a chromatograph (Clarus
500, Pelkin Elmer, Beaconsfield, UK) equipped with a VF-
23 column (30m × 0.25 nm × 0.25 𝜇m, Varian, Middelburg,
Netherlands). For GLC analysis, the initial temperature was
80∘C. Then, the temperature was increased to 170∘C at
30∘Cmin−1, held at 170∘C for 3min, increased to 230∘C at
30∘Cmin−1 and, and finally held at 230∘C for 7min. Helium
was used as the carrier gas at a pressure of 15 psig and
with a split ratio of 1 : 50. The injection volume was 0.5 𝜇L
and the analysis time was 15min. Peaks were identified by
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comparing the retention times of CLA methylated standards
(Nucheck, USA) and by gas chromatography-mass spec-
trometry (GC/MS). CLA and CLNA concentrations were
expressed as 𝜇gmL−1 and their conversion rates from LA and
LNAwere calculated using the formula [CLA/(CLA + LA)] ×
100 and [CLNA/(CLNA + LNA)] × 100, respectively.
3. Results
The eight bifidobacterial strains assayed in this work were
screened spectrophotometrically at A
233
for CLA production
from the LA added to the growth media, following the rapid
method described by [10]. With this approach, a total of 3
strains (Bifidobacterium breve ZL12-28, B. breve 29M2, and
B. breveM7-70) were identified as able to transform LA into
CLA (Table 1).
Subsequently, each of the three selected CLA-producing
strains was assayed for CLA and CLNA production by GLC
determination after incubation for 24 h at 37∘C in MRS-Cys
and skim milk (Tables 2 and 4). The concentration of CLA
produced by the selected Bifidobacterium strains reached
values above 158.7 𝜇gmL−1, indicating that the minimal
conversion rate from the added LA was approximately 74%.
The bacterial strains were able to produce different CLA
isomers, such as cis 9, trans 11 CLA, trans 10, cis 12 CLA
and trans 9, trans 11 CLA (Figure 1); among them, cis 9,
trans 11 CLA (rumenic acid) was the most abundant isomer,
accounting for more than 80% of the total CLA in all cases
(Table 2). As it has been reported,many bacteria are inhibited
by free long-chain fatty acids in the media [18]; however, B.
breveM7-70 was able to grow in the presence of LA and LNA
at concentrations up to 1500 and 500 𝜇gmL−1, respectively
(Table 3).
Production of CLNA in MRS-Cys by B. breve strains was
higher than that of CLA since the concentrations found in
the respective culture media were higher than 200 𝜇gmL−1,
and the LNA to CLNA conversion rate was close to 100%
(Table 2). Two CLNA isomers (cis 9, trans 11, cis 15 CLNA
and trans 9, trans 11, cis 15 CLNA) could be detected in the
chromatogram profiles (Figure 2), and cis 9, trans 11, cis 15
CLNA (rumenic acid) accounted for approximately 80% of
the total amount of CLNA in the cultures of the three strains
(Table 2).The conversion of LNA to CLNA by B. breveM7-70
in MRS-Cys was faster than that of LA to CLA since CLNA
production began after 2 h incubation at 37∘C while CLA
formation required at least 6 h of incubation to be detected
(Figure 3).
Subsequently, the three selected bifidobacterial strains
were assayed for CLA and/or CLNA production in the milk-
basedmedium after 24 h incubation at 37∘C. CLA production
was above 75𝜇gmL−1 for the three B. breve strains (Table 4).
Both CLA production and LA conversion rate were lower in
milk than in MRS-Cys. As expected, the predominant CLA
isomer produced in reconstituted skim milk was cis 9, trans
11CLA, accounting formore than 80% of total CLA (Table 4).
All the selected strains were able to produce CLNA
when growing in the milk-based medium. In this case, the
concentration of CLNA produced by these bifidobacteria
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Figure 1: (a) Chromatogram profile assessed by gas chromatogra-
phy of the fatty acid content present in the culture media obtained
from B. breve M7-70 in MRS broth with 500𝜇gmL−1 LA added
as a substrate. (b) The insert shows a blow-up of the part of the
chromatogram corresponding to the CLA isomers.
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Figure 2: (a) Chromatogram profile assessed by gas chromatogra-
phy of the fatty acid content present in the culture media obtained
from B. breve M7-70 in MRS broth with 500 𝜇gmL−1 LNA as
a substrate. (b) The insert shows a blow-up of the part of the
chromatogram corresponding to the CLNA isomers.
(200𝜇gmL−1) and the conversion rates (∼100%) were similar
to those observed in MRS-Cys broth (Table 4). Rumenic acid
was also the dominant isomer, accounting for approximately
90% of the CLNA total amount.
Finally, the three selected bifidobacterial strains were
tested for their ability to produce CLA and CLNA when
both substrates (LA and LNA) were added to the milk-
based medium. The three B. breve strains were able to
simultaneously produce CLA and CLNA in these growth
conditions (Figure 4). The CLA and CLNA concentrations
produced were about 100𝜇gmL−1 of CLA and 300𝜇gmL−1
of CLNA (Figure 4). Interestingly, the production of both
bioactive lipids was much higher when both substrates, LA
and LNA, were present at the same time in the growing
medium than when they were individually added (Table 4
and Figure 4).
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Table 2: CLA and CLNA production (𝜇gmL−1) and conversion (%) of LA and LNA by the bifidobacterial strains when growing inMRS-Cys.
Conversion calculated as ∑CLA/(LA + ∑CLA) × 100 and ∑CLNA/(LNA + ∑CLNA) × 100, respectively, based on the results of GC.
Strains CLA cis 9 trans 11(% CLA) LA conversion (%) CLNA
cis 9 trans 11 cis 15
(% CLNA) LNA conversion (%)
B. breve ZL12-28 170.6 ± 38.5 (a) 81.2 ± 0.8 (a) 74.6 ± 6.2 (a) 218.8 ± 39.0 (a) 82.7 ± 8.7 (a) 98.8 ± 0.6 (a)
B. breve 29M2 158.7 ± 48.3 (a) 85.6 ± 0.7 (b) 74.1 ± 7.0 (a) 211.6 ± 59.3 (a) 91.4 ± 3.2 (a) 95.7 ± 4.8 (a)
B. breveM7-70 170.3 ± 46.4 (a) 81.7 ± 1.0 (a) 77.8 ± 2.8 (a) 234.2 ± 81.5 (a) 85.7 ± 3.3 (a) 98.7 ± 0.9 (a)
Values are means of triplicate experiments and standard deviation (±SD).
Means in the same column with different lowercase letters are significant at 𝑃 < 0.05.
Table 3: Growth of B. breve M7-70 in the presence of different
concentrations of LA and LNA.
Concentration
(mgmL−1) LA LNA
0 +++∗ +++
0.25 ++ +
0.50 ++ +
1.0 + −
1.5 + −
2.0 − −
∗(−) No growth; (+) slight growth; (++) moderate growth; (+++) optimal
growth. All the bifidobacterial strains assayed showed the same level of
inhibition.
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Figure 3: Comparative analysis of CLA versus CLNA production
at different times. The B. breveM7-70 strain was incubated in MRS
broth containing 500 𝜇gmL−1 free linoleic acid (LA) or 500𝜇gmL−1
free linolenic acid (LNA) for 48 hours under anaerobic conditions.
Samples were taken at the indicated times. Values are means ± SD of
three independent experiments.
4. Discussion
Bifidobacteria are numerically important members of the
human gut microbiota and are believed to play a beneficial
role in maintaining the health of the host. Some studies have
suggested that infants with delayed bifidobacterial coloniza-
tion and/or decreased bifidobacterial numbers may be more
susceptible to a variety of gastrointestinal or allergic condi-
tions [19, 20]. In these cases, the exogenous administration
of selected bifidobacterial strains, alone or in combination
with lactic acid bacteria, can reduce the incidence of such
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Figure 4: CLA/CLNA production by selected bacteria of screening.
The cultures were incubated in reconstituted skim milk containing
500 𝜇gmL−1 free linoleic acid (LA) and 500 𝜇gmL−1 free linolenic
acid (LNA) for 24 hours under anaerobic conditions. Values are
means ± SD of three independent experiments.
conditions [21–23].Therefore, bifidobacteria are generally re-
garded as potentially probiotic microorganisms.
Recently, it has been shown that human milk is a source
of live lactic acid bacteria and bifidobacteria to the infant
gastrointestinal tract [24, 25]. If health benefits could be
associated with bifidobacterial strains isolated from such
biological fluid, then they would be immediately regarded as
particularly attractivemicroorganisms since they would fulfil
some of the main criteria generally recommended for human
probiotics, such as human origin and adaptation to mucosal
and dairy substrates [26, 27].
Since production of conjugated fatty acids by some
bifidobacteria and lactic acid bacteria has been reported in
the last years [1, 2, 12, 28], it is considered of interest to
have human milk strains available with such capability. In
this work, we describe the assayed conditions to select and
characterize three B. breve strains with the ability to produce
high amounts of CLA and CLNA during their growth in
skim milk. It is not strange that the selection process ended
with three strains belonging to the species B. breve, since this
species seems to be particularly suited for production of these
bioactive lipids [28–31]. The bioactive lipid production is a
strain-specific attribute and, in fact, a non-CLA-producing B.
breve strain (B. breve ZL12-22) was also found in this study.
It has been hypothesized that some bacteria can convert
LA to CLA and LNA to CLNA as a detoxification mechanism
BioMed Research International 5
Table 4: CLAandCLNAproduction (𝜇gmL−1) and conversion (%) of LA andLNAbyB. breve strainswhen growing in skimmilk. Conversion
calculated as ∑CLA/(LA + ∑CLA) × 100 and ∑CLNA/(LNA + ∑CLNA) × 100, respectively, based on the results of GC.
Strains CLA cis 9 trans 11(% CLA) LA conversion (%) CLNA
cis 9 trans 11 cis 15
(% CLNA) LNA conversion (%)
B. breve ZL12-28 75.0 ± 9.5 (a) 83.6 ± 5.3 (a) 31.3 ± 14 (a) 243.7 ± 39.8 (a) 93.6 ± 0.8 (a) 96.5 ± 1.2 (a)
B. breve 29M2 95.0 ± 12.4 (a) 87.0 ± 6.6 (a) 41.6 ± 11 (a) 219.8 ± 30 (a) 90.4 ± 4.2 (a) 94.0 ± 6.5 (a)
B. breveM7-70 75.9 ± 6.1 (a) 83.4 ± 4.1 (a) 29.6 ± 12 (a) 210.1 ± 23.8 (a) 90.9 ± 1.9 (a) 97.0 ± 1.4 (a)
Values are means of triplicate experiments and standard deviation (±SD).
Means in the same column with different lowercase letters are significant at 𝑃 < 0.05.
[18, 28, 29, 32]. LA and LNA have antimicrobial activity and
may alter the permeability of the plasmatic membrane of
some Gram-positive bacteria [33]. It has been shown that
both substrates have inhibitory effects on the growth of CLA
and CLNA producing strains [28, 34]. Generally, free LNA
is more toxic to bacteria than free LA, which is coincident
with the results obtained in this work with B. breve M7-70.
The hypothesis of the detoxification mechanism may explain
why CLNA production by the three B. breve strains was more
efficient than CLA production. It also could explain why the
production of both CLA and CLNA was higher when both
substrates were added together than when the strains were
grown on each substrate separately (Table 4 and Figure 4).
At present, CLA is better characterised thanCLNA.There
are some research works that report the health-promoting
properties of CLNA [1]. A recent study demonstrated the
ability of a B. breve strain to produce CLNA and other
conjugated fatty acids, such as conjugated 𝛾-linolenic acid
(CGLA) or conjugated stearidonic acid (CSA), from 𝛾-
linolenic acid and stearidonic acid, respectively [35]. Another
work reported that B. breve NCIMB 702258 displayed a high
conversion rate (79%) of 𝛼-linolenic acid into the cis 9 trans
11 cis 15 CLNA isomer. This isomer can inhibit the growth
of SW480 colon cancer cells [31]. All these mentioned works
have described the CLNA production during growth of the
strains in MRS broth. In contrast, the results of our study
indicate that the selected B. breve strains were able to produce
significant amounts of CLNA (200𝜇gmL−1) in skim milk,
with a conversion rate of LNA close to 100%. In addition,
this study has demonstrated that B. breve strains were able
to coproduce high levels of CLA and CLNA during growth in
skimmilk. Coproduction of CLA and CLNA in the described
concentrations would be of relevance to increase the amount
of these bioactive lipids in fermented milks. Globally, these
results suggest that the three selected B. breve strains have a
strong potential to be used as probiotics in fermented milks
in order to increase human intake of CLA andCLNA. Further
studies to optimize the culture conditions for increasing
CLA and CLNA production at large-scale by fermentation
processes would be needed. Additional studies will be also
required to further elucidate the relevance of consumption of
these bioactive lipids in human health.
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